RT Journal Article
SR Electronic
T1 A2B-COVID: A method for evaluating potential SARS-CoV-2 transmission events
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.26.20219642
DO 10.1101/2020.10.26.20219642
A1 Christopher J. R. Illingworth
A1 William L. Hamilton
A1 Chris Jackson
A1 Ashley Popay
A1 Luke Meredith
A1 Charlotte J. Houldcroft
A1 Myra Hosmillo
A1 Aminu Jahun
A1 Matthew Routledge
A1 Ben Warne
A1 Laura Caller
A1 Sarah Caddy
A1 Anna Yakovleva
A1 Grant Hall
A1 Fahad A. Khokhar
A1 Theresa Feltwell
A1 Malte L. Pinckert
A1 Iliana Georgana
A1 Yasmin Chaudhry
A1 Martin Curran
A1 Surendra Parmar
A1 Dominic Sparkes
A1 Lucy Rivett
A1 Nick K. Jones
A1 Sushmita Sridhar
A1 Sally Forrest
A1 Tom Dymond
A1 Kayleigh Grainger
A1 Chris Workman
A1 Effrossyni Gkrania-Klotsas
A1 Nicholas M. Brown
A1 Michael P. Weekes
A1 Stephen Baker
A1 Sharon J. Peacock
A1 Theodore Gouliouris
A1 Ian Goodfellow
A1 Daniela de Angelis
A1 M. Estée Török
YR 2020
UL http://medrxiv.org/content/early/2020/10/27/2020.10.26.20219642.abstract
AB Identifying linked cases of infection is a key part of the public health response to viral infectious disease. Viral genome sequence data is of great value in this task, but requires careful analysis, and may need to be complemented by additional types of data. The Covid-19 pandemic has highlighted the urgent need for analytical methods which bring together sources of data to inform epidemiological investigations. We here describe A2B-COVID, an approach for the rapid identification of linked cases of coronavirus infection. Our method combines knowledge about infection dynamics, data describing the movements of individuals, and novel approaches to genome sequence data to assess whether or not cases of infection are consistent or inconsistent with linkage via transmission. We apply our method to analyse and compare data collected from two wards at Cambridge University Hospitals, showing qualitatively different patterns of linkage between cases on designated Covid-19 and non-Covid-19 wards. Our method is suitable for the rapid analysis of data from clinical or other potential outbreak settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by COG-UK, which is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute; We also acknowledge the support from the Wellcome (Senior Clinical Fellowship to MPW (ref: 108070/Z/15/Z), Senior Research Fellowship to SB (ref: 215515/Z/19/Z), Senior Fellowship to IG (ref: 097997/Z/11/Z); Collaborative Grant to CJH (ref: 204870/Z/16/Z); the Academy of Medical Sciences & the Health Foundation (Clinician Scientist Fellowship to MET), the NIHR Cambridge Biomedical Research Centre (to BW, MET) and the NIHR Clinical Research Network Greenshoots award (to EGK). CJRI was supported by Deutsche Forschungsgemeinschaft (DFG) Grant SFB 1310. We acknowledge MRC funding (ref: MC_UU_00002/11).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted as part of surveillance for COVID-19 infections under the auspices of Section 251 of the NHS Act 2006. It therefore did not require individual patient consent or ethical approval. The COG-UK study protocol was approved by the Public Health England Research Ethics Governance Group (reference: R&D NR0195).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data analysed were generated by previous research studies and are available from the GISAID server. A list of sequence IDs are provided in Supplementary Material. Sequences and accompanying metadata has been uploaded onto the MRC-CLIMB server. https://www.gisaid.org https://www.climb.ac.uk/